• Vk
  • LinkedIn
  • Youtube
X7 Research
  • News
  • Registration strategy and Сonsulting
    • Budgeting
    • Registration strategy development
    • Study feasibility
    • Vendor selection
    • Data search and analysis
  • Clinical trials
    • Outsourcing CRAs in Russia and the EAEU
    • Development of medical documentation and biostatistics
    • Monitoring
    • Data-management
    • Patient home visits
    • Bioequivalence study
    • Therapeutic equivalence studies
    • Clinical trials of medical devices
  • Registration
    • Audit of the registration dossier
    • Bringing the registration dossier in compliance with the requirements of the EAEU
    • Conversion of registration dossier into XML format
    • PIL readability user testing
    • Translation of the Registration dossier
    • Turnkey registration
  • Post-authorization clinical studies
    • Phase IV studies
    • Non-interventional studies
    • Investigator-initiated studies
    • Post-authorisation safety study
    • Marketing research
  • Pharmacovigilance
    • QPPV in the EAEU
    • Safety monitoring of medical devices
    • Building a pharmacovigilance system
    • Safety in clinical trials
    • Pharmacovigilance audit
    • Pharmacovigilance contact person
  • Therapeutic expertise
    • Clinical trials in Oncology in the EAEU
  • Contact
  • EnglishEnglish
    • РусскийРусский
  • Menu

Acceptance of results of clinical trials conducted in Russia for registration in European Union and US

08.12.2016/in News /by X7 Research

Clinical trials including multinational and multicenter ones are conducted in Russian Federation since the beginning of 90ies of XX century, and it was involvement of Russia into the international clinical trial market that promoted development, improvement and harmonization of the regulatory and ethical requirements for the conduct of such trial in the country. Over relatively short period compared to other countries (less than 20 years) Russian Federation changed several “generation” of regulations and guidelines in clinical trials. Good Clinical Practice (GCP) was adopted as national standard (GOST) in Russia in 2006 being the almost literal translation of the corresponding International Conference for Harmonization (ICH) guideline. Federal Law ФЗ-61 “On the circulation of medicines” entered force in 2010 that, with its numerous amendments introduced from 2010 till 2016, gradually harmonized standard of submission and conduct of clinical trials as well as registration of new medicines, with international standards.

Since 2011 (soon after the start of action of ФЗ-61) Scientific center for expertise of medical products attached to Russian Ministry of Healthcare started developing and publishing guidelines for industry and own experts in conduct and expertise of pre-clinical and clinical trials of medicines that were largely based on ICH guidelines, European Medicines Agency (EMEA) scientific guidelines and Food and Drug Administration (FDA) guidances. Guidelines on good clinical practices were clarified and enriched and approved by the Order of Russian Ministry of Healthcare. Finally, by the end of 2016 long list of regulations of Eurasian Economic Union will enter force including those related to clinical trials that will further harmonize procedures of registration and control in the circulation of medicines in Russia and EU/US.

Moreover, active collaboration of EU and US regulatory agencies with Russian Ministry of Healthcare in drug registration and pharmacovigilance is ongoing for at least 10 last years. As part of the dialogue between EU and Russia, a subgroup on pharmaceuticals was established in 2007. Since then this group actively involves EMEA in the discussions related to scientific and technical issues of registration and circulation of medicines. Memorandum of understanding was renewed again between U.S. Pharmacopeial Convention (USP) and Federal Service on Surveillance in Healthcare (Roszdravnadzor) of Russian Federation in October 2015, reinforcing collaboration in the area of regulation of pharmacopeial requirements and good laboratory practice in Russia and US. A similar memorandum was signed almost immediately after that between FDA and Roszdravnadzor in the area of clinical trials and registration of medicines. Roszdravnadzor experts regularly visit USP and FDA to participate in training and improve their skills that are also adding to further rapprochement of understanding of clinical trial conduct by regulators in both countries.

Consequently, Russian Federation managed to developed a solid (yet, continuously evolving) system of control over development and conduct of pre-clinical and clinical trials for pharmaceutical agents, and experts of Russian Ministry of Healthcare are sometimes even stricter compared to their colleagues in EMEA and FDA, following national and international clinical trial regulations and guidelines literally. For example, until recent medicines for oral intake without systemic absorption were treated by Russian experts only as medicines that correspondingly assumed the certain volume of preclinical and clinical study data, while EMEA standards allow registration of some medicines of that kind as medical devices that assumes less clinical and preclinical data. Analysis of rejections or comments provided by Russian Ministry of Healthcare for clinical study protocols that were approved at the same time in other countries of the region showed that Russian experts conduct a profound review of protocol text and require strict adherence to ethical and regulatory standards. Ever increasing the amount of Roszdravnadzor inspection of clinical trials assured high data quality, and the latter is support by the results of multiple regulatory inspections conducted by EMEA and FDA – percentage of inspections without major findings is the highest in Russia compared to other countries in the region.

Accordingly, over the last 10 years, several western pharmaceutical companies started using clinical study data from trials conducted in Russian Federation more and more broadly, for both new and generic drugs. It is widely known that such new medicines as Tykerb (GSK), Ixempra (BMS) and Mircera (Roche) were registered in EU and US based on the study results from trials where Russian population took a major part. Novartis registered Gilenya in Russian Federation earlier than in any other country including US and EU based on the registration dossier containing fingolimod clinical study results from a clinical trial with major participation of Russian patients with multiple sclerosis.

Registration dossier of Abraxane (generic paclitaxel) that is currently registered in EU and US, contains substantial proportion of data from Russia – half of Phase I trials were conducted in Russian Federation exclusively, and proportion of patients from Russia and Ukraine reached 80% in pivotal Phase III study (it should be noted that Russian clinical sites amounted only 25% of all active sites in this study).

Clinical study results from the trials conducted in Russia are not used by international pharmaceutical companies only. Russian company R-Pharm, after consultations with FDA in 2015, got approval for a large-scale program of clinical trials of olokizumab (monoclonal antibody for the treatment of rheumatoid arthritis) in Russian Federation and the US, with Russian population expected to prevail in all clinical trials of this program.

Thus, recent experience clearly shows that clinical study results from trials conducted in Russian Federation or with substantial involvement of Russian patients are reviewed and accepted by EU and US regulatory agencies. Moreover, high data quality and availability of diverse patient populations in more than 1000 investigative sites make Russia quite attractive for industry.

Share this entry
  • Share on Twitter
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn
  • Share on Tumblr
  • Share on Vk
  • Share on Reddit
  • Share by Mail

YOU MAY ALSO BE INTERESTED IN

Publications
Readability User Testing of Package Information Leaflets (PIL) in EAEU
Read More
Publications
Remote clinical trial monitoring
Read More
Publications
Post-authorization studies of drug safety in Russia
Read More

RUBRICS

Registration strategy and Сonsulting

Clinical trials

Registration

Post-authorization clinical studies

Pharmacovigilance

LATEST PUBLICATIONS

  • Corrections to clinical trial documents due to COVID-19. Russian experience.
  • WHAT IS BIOEQUIVALENCE
  • THE VOLUME OF RUSSIAN PHARMACEUTICAL MARKET 2016-2019

Tags

bioequivalenceClinical trials in the CISfeasibilitymonitoringRadiopharmaceuticals

CONTACT

0 + 5 = ?

This contact form is deactivated because you refused to accept Google reCaptcha service which is necessary to validate any messages sent by the form.

PRIVACY

Use of this site constitutes your consent to our Privacy Policy.


SOCIAL RESPONSIBILITY

X7 Research’s primary responsibility is to help our clients in bringing medicines & products to the market efficiently and safely.

The Best CRO for Clinical Trials | Full-service Global CRO — X7 Research

The Best CRO in Pharma | Clinical Research Organisation — X7 Research

The Best Contract Research Organisation (CRO) | Trusted CRO — X7 Research

The Best Clinical Research Organisation (CRO): Full Service CRO | X7 Research

The Best CRO in Research | Trusted CRO for Your Trail — X7 Research

The Best Clinical Trial Company | Global Full-service CRO - X7 Research

The Best Pharma CROs: Clinical Trials for Drugs | X7 Research

The Best CROs Company: Clinical Trials with Global CRO — X7 Research

The Best Pre-clinical CRO: Safety Assessment With X7 Research

The Best Clinical Development | Trusted CRO for Your Product: X7 Research

The Best Biostatistical Consulting: Statistical Services | X7 Research

The Best Pharmacovigilance Consulting Services | CRO — X7 Research

Feasibility in Clinical Trials: What is a Feasibility in Clinical Trials?

Clinical Study Trials: What are Clinical Study Trials?

Category
Strategy and consulting
Clinical trials
Registration
Post-authorization clinical studies
Pharmacovigilance

Registration strategy and Сonsulting
Registration strategy development
Budgeting
Study feasibility
Vendor selection
Data search and analysis

Clinical trials
Development of medical documentation and biostatistics
Monitoring
Data management
Patient home visits
Bioequivalence study
Therapeutic equivalence studies

Registration
Audit of the registration dossier
Dossier eaeu
Conversion of registration dossier into xml format
Pil readability user testing
Turnkey registration

Post-authorization clinical studies
Phase iv studies
Non interventional studies
Investigator initiated studies
Post authorisation safety study
Marketing research

Pharmacovigilance
Building a pharmacovigilance system
Safety in clinical trials
Pharmacovigilance audit
Pharmacovigilance contact person

Blog
Contacts

© Copyright 2010-2023 - X7 Research. All rights reserved.
Solanezumab for Alzheimer’s: the truth is still out there FDA pharmacovigilance approach is strict but flexible
Scroll to top